APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Waldenstrom Macroglobulinemia Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Waldenstrom Macroglobulinemia Therapeutics Market Analysis and Forecast 2026-2032

Report ID 174047290226 December 2025197 pages

Choose your research edition.

Industry ResearchWaldenstrom Macroglobulinemia Therapeutics Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Waldenstrom Macroglobulinemia Therapeutics Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Waldenstrom Macroglobulinemia Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Waldenstrom Macroglobulinemia Therapeutics Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Waldenstrom Macroglobulinemia Therapeutics Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Waldenstrom Macroglobulinemia Therapeutics market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Waldenstrom Macroglobulinemia Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Waldenstrom Macroglobulinemia Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Waldenstrom Macroglobulinemia Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Waldenstrom Macroglobulinemia Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Waldenstrom Macroglobulinemia Therapeutics include Merck KGaA, Millennium Pharmaceuticals, Inc., Karyopharm Therapeutics, Inc., Incyte Corporation, IGF Oncology, LLC., Idera Pharmaceuticals, Inc., Hutchison MediPharma Limited, Gilead Sciences, Inc. and Genmab A/S, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Waldenstrom Macroglobulinemia Therapeutics, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Waldenstrom Macroglobulinemia Therapeutics, also provides the sales of main regions and countries. Of the upcoming market potential for Waldenstrom Macroglobulinemia Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Waldenstrom Macroglobulinemia Therapeutics sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Waldenstrom Macroglobulinemia Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Waldenstrom Macroglobulinemia Therapeutics sales, projected growth trends, production technology, application and end-user industry.

Waldenstrom Macroglobulinemia Therapeutics Segment by Company

Merck KGaA

Millennium Pharmaceuticals, Inc.

Karyopharm Therapeutics, Inc.

Incyte Corporation

IGF Oncology, LLC.

Idera Pharmaceuticals, Inc.

Hutchison MediPharma Limited

Gilead Sciences, Inc.

Genmab A/S

Genentech, Inc.

Celgene Corporation

Calithera Biosciences, Inc.

BeiGene(Beijing) Co.,Ltd

Waldenstrom Macroglobulinemia Therapeutics Segment by Type

CB-839

DI-B4

FV-162

Entospletinib

Copanlisib Hydrochloride

Everolimus

Others

Waldenstrom Macroglobulinemia Therapeutics Segment by Application

Clinic

Hospital

Others

Waldenstrom Macroglobulinemia Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Waldenstrom Macroglobulinemia Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Waldenstrom Macroglobulinemia Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Waldenstrom Macroglobulinemia Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Waldenstrom Macroglobulinemia Therapeutics in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Waldenstrom Macroglobulinemia Therapeutics manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Waldenstrom Macroglobulinemia Therapeutics sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Waldenstrom Macroglobulinemia Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. CB-839 Major Manufacturers Table 3. DI-B4 Major Manufacturers Table 4. FV-162 Major Manufacturers Table 5. Entospletinib Major Manufacturers Table 6. Copanlisib Hydrochloride Major Manufacturers Table 7. Everolimus Major Manufacturers Table 8. Others Major Manufacturers Table 9. Global Waldenstrom Macroglobulinemia Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 10. Clinic Major Manufacturers Table 11. Hospital Major Manufacturers Table 12. Others Major Manufacturers Table 13. Waldenstrom Macroglobulinemia Therapeutics Industry Trends Table 14. Waldenstrom Macroglobulinemia Therapeutics Industry Drivers Table 15. Waldenstrom Macroglobulinemia Therapeutics Industry Opportunities and Challenges Table 16. Waldenstrom Macroglobulinemia Therapeutics Industry Restraints Table 17. Global Waldenstrom Macroglobulinemia Therapeutics Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Region (2021-2026) & (US$ Million) Table 19. Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Region (2027-2032) & (US$ Million) Table 20. Global Waldenstrom Macroglobulinemia Therapeutics Revenue Market Share by Region (2021-2026) Table 21. Global Waldenstrom Macroglobulinemia Therapeutics Revenue Market Share by Region (2027-2032) Table 22. Global Waldenstrom Macroglobulinemia Therapeutics Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (W Units) Table 23. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Region (2021-2026) & (W Units) Table 24. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Region (2027-2032) & (W Units) Table 25. Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share by Region (2021-2026) Table 26. Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share by Region (2027-2032) Table 27. Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Manufacturers (US$ Million) & (2021-2026) Table 28. Global Waldenstrom Macroglobulinemia Therapeutics Revenue Market Share by Manufacturers (2021-2026) Table 29. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Manufacturers (US$ Million) & (2021-2026) Table 30. Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share by Manufacturers (2021-2026) Table 31. Global Waldenstrom Macroglobulinemia Therapeutics Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 32. Global Waldenstrom Macroglobulinemia Therapeutics Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 33. Global Waldenstrom Macroglobulinemia Therapeutics Key Manufacturers Manufacturing Sites & Headquarters Table 34. Global Waldenstrom Macroglobulinemia Therapeutics Manufacturers, Product Type & Application Table 35. Global Waldenstrom Macroglobulinemia Therapeutics Manufacturers' Establishment Date Table 36. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 37. Global Waldenstrom Macroglobulinemia Therapeutics by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 38. Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 40. Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 41. Global Waldenstrom Macroglobulinemia Therapeutics Revenue Market Share by Type (2021-2026) Table 42. Global Waldenstrom Macroglobulinemia Therapeutics Revenue Market Share by Type (2027-2032) Table 43. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 44. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Type (2021-2026) & (W Units) Table 45. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Type (2027-2032) & (W Units) Table 46. Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share by Type (2021-2026) Table 47. Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share by Type (2027-2032) Table 48. Global Waldenstrom Macroglobulinemia Therapeutics Price by Type (2021-2026) & (US$/Unit) Table 49. Global Waldenstrom Macroglobulinemia Therapeutics Price by Type (2027-2032) & (US$/Unit) Table 50. Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 52. Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 53. Global Waldenstrom Macroglobulinemia Therapeutics Revenue Market Share by Application (2021-2026) Table 54. Global Waldenstrom Macroglobulinemia Therapeutics Revenue Market Share by Application (2027-2032) Table 55. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 56. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Application (2021-2026) & (W Units) Table 57. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Application (2027-2032) & (W Units) Table 58. Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share by Application (2021-2026) Table 59. Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share by Application (2027-2032) Table 60. Global Waldenstrom Macroglobulinemia Therapeutics Price by Application (2021-2026) & (US$/Unit) Table 61. Global Waldenstrom Macroglobulinemia Therapeutics Price by Application (2027-2032) & (US$/Unit) Table 62. Merck KGaA Company Information Table 63. Merck KGaA Business Overview Table 64. Merck KGaA Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 65. Merck KGaA Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 66. Merck KGaA Recent Development Table 67. Millennium Pharmaceuticals, Inc. Company Information Table 68. Millennium Pharmaceuticals, Inc. Business Overview Table 69. Millennium Pharmaceuticals, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Millennium Pharmaceuticals, Inc. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 71. Millennium Pharmaceuticals, Inc. Recent Development Table 72. Karyopharm Therapeutics, Inc. Company Information Table 73. Karyopharm Therapeutics, Inc. Business Overview Table 74. Karyopharm Therapeutics, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Karyopharm Therapeutics, Inc. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 76. Karyopharm Therapeutics, Inc. Recent Development Table 77. Incyte Corporation Company Information Table 78. Incyte Corporation Business Overview Table 79. Incyte Corporation Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Incyte Corporation Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 81. Incyte Corporation Recent Development Table 82. IGF Oncology, LLC. Company Information Table 83. IGF Oncology, LLC. Business Overview Table 84. IGF Oncology, LLC. Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. IGF Oncology, LLC. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 86. IGF Oncology, LLC. Recent Development Table 87. Idera Pharmaceuticals, Inc. Company Information Table 88. Idera Pharmaceuticals, Inc. Business Overview Table 89. Idera Pharmaceuticals, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Idera Pharmaceuticals, Inc. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 91. Idera Pharmaceuticals, Inc. Recent Development Table 92. Hutchison MediPharma Limited Company Information Table 93. Hutchison MediPharma Limited Business Overview Table 94. Hutchison MediPharma Limited Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Hutchison MediPharma Limited Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 96. Hutchison MediPharma Limited Recent Development Table 97. Gilead Sciences, Inc. Company Information Table 98. Gilead Sciences, Inc. Business Overview Table 99. Gilead Sciences, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Gilead Sciences, Inc. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 101. Gilead Sciences, Inc. Recent Development Table 102. Genmab A/S Company Information Table 103. Genmab A/S Business Overview Table 104. Genmab A/S Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Genmab A/S Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 106. Genmab A/S Recent Development Table 107. Genentech, Inc. Company Information Table 108. Genentech, Inc. Business Overview Table 109. Genentech, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Genentech, Inc. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 111. Genentech, Inc. Recent Development Table 112. Celgene Corporation Company Information Table 113. Celgene Corporation Business Overview Table 114. Celgene Corporation Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Celgene Corporation Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 116. Celgene Corporation Recent Development Table 117. Calithera Biosciences, Inc. Company Information Table 118. Calithera Biosciences, Inc. Business Overview Table 119. Calithera Biosciences, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Calithera Biosciences, Inc. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 121. Calithera Biosciences, Inc. Recent Development Table 122. BeiGene(Beijing) Co.,Ltd Company Information Table 123. BeiGene(Beijing) Co.,Ltd Business Overview Table 124. BeiGene(Beijing) Co.,Ltd Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. BeiGene(Beijing) Co.,Ltd Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 126. BeiGene(Beijing) Co.,Ltd Recent Development Table 127. North America Waldenstrom Macroglobulinemia Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 128. North America Waldenstrom Macroglobulinemia Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 129. North America Waldenstrom Macroglobulinemia Therapeutics Sales by Type (2021-2026) & (W Units) Table 130. North America Waldenstrom Macroglobulinemia Therapeutics Sales by Type (2027-2032) & (W Units) Table 131. North America Waldenstrom Macroglobulinemia Therapeutics Sales Price by Type (2021-2026) & (US$/Unit) Table 132. North America Waldenstrom Macroglobulinemia Therapeutics Sales Price by Type (2027-2032) & (US$/Unit) Table 133. North America Waldenstrom Macroglobulinemia Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 134. North America Waldenstrom Macroglobulinemia Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 135. North America Waldenstrom Macroglobulinemia Therapeutics Sales by Application (2021-2026) & (W Units) Table 136. North America Waldenstrom Macroglobulinemia Therapeutics Sales by Application (2027-2032) & (W Units) Table 137. North America Waldenstrom Macroglobulinemia Therapeutics Sales Price by Application (2021-2026) & (US$/Unit) Table 138. North America Waldenstrom Macroglobulinemia Therapeutics Sales Price by Application (2027-2032) & (US$/Unit) Table 139. North America Waldenstrom Macroglobulinemia Therapeutics Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 140. North America Waldenstrom Macroglobulinemia Therapeutics Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 141. North America Waldenstrom Macroglobulinemia Therapeutics Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 142. North America Waldenstrom Macroglobulinemia Therapeutics Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 143. North America Waldenstrom Macroglobulinemia Therapeutics Sales by Country (2021-2026) & (W Units) Table 144. North America Waldenstrom Macroglobulinemia Therapeutics Sales by Country (2027-2032) & (W Units) Table 145. North America Waldenstrom Macroglobulinemia Therapeutics Sales Price by Country (2021-2026) & (US$/Unit) Table 146. North America Waldenstrom Macroglobulinemia Therapeutics Sales Price by Country (2027-2032) & (US$/Unit) Table 147. United States Waldenstrom Macroglobulinemia Therapeutics Revenue (2021-2032) & (US$ Million) Table 148. Canada Waldenstrom Macroglobulinemia Therapeutics Revenue (2021-2032) & (US$ Million) Table 149. Mexico Waldenstrom Macroglobulinemia Therapeutics Revenue (2021-2032) & (US$ Million) Table 150. Europe Waldenstrom Macroglobulinemia Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 151. Europe Waldenstrom Macroglobulinemia Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 152. Europe Waldenstrom Macroglobulinemia Therapeutics Sales by Type (2021-2026) & (W Units) Table 153. Europe Waldenstrom Macroglobulinemia Therapeutics Sales by Type (2027-2032) & (W Units) Table 154. Europe Waldenstrom Macroglobulinemia Therapeutics Sales Price by Type (2021-2026) & (US$/Unit) Table 155. Europe Waldenstrom Macroglobulinemia Therapeutics Sales Price by Type (2027-2032) & (US$/Unit) Table 156. Europe Waldenstrom Macroglobulinemia Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 157. Europe Waldenstrom Macroglobulinemia Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 158. Europe Waldenstrom Macroglobulinemia Therapeutics Sales by Application (2021-2026) & (W Units) Table 159. Europe Waldenstrom Macroglobulinemia Therapeutics Sales by Application (2027-2032) & (W Units) Table 160. Europe Waldenstrom Macroglobulinemia Therapeutics Sales Price by Application (2021-2026) & (US$/Unit) Table 161. Europe Waldenstrom Macroglobulinemia Therapeutics Sales Price by Application (2027-2032) & (US$/Unit) Table 162. Europe Waldenstrom Macroglobulinemia Therapeutics Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 163. Europe Waldenstrom Macroglobulinemia Therapeutics Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 164. Europe Waldenstrom Macroglobulinemia Therapeutics Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 165. Europe Waldenstrom Macroglobulinemia Therapeutics Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 166. Europe Waldenstrom Macroglobulinemia Therapeutics Sales by Country (2021-2026) & (W Units) Table 167. Europe Waldenstrom Macroglobulinemia Therapeutics Sales by Country (2027-2032) & (W Units) Table 168. Europe Waldenstrom Macroglobulinemia Therapeutics Sales Price by Country (2021-2026) & (US$/Unit) Table 169. Europe Waldenstrom Macroglobulinemia Therapeutics Sales Price by Country (2027-2032) & (US$/Unit) Table 170. Germany Waldenstrom Macroglobulinemia Therapeutics Revenue (2021-2032) & (US$ Million) Table 171. France Waldenstrom Macroglobulinemia Therapeutics Revenue (2021-2032) & (US$ Million) Table 172. U.K. Waldenstrom Macroglobulinemia Therapeutics Revenue (2021-2032) & (US$ Million) Table 173. Italy Waldenstrom Macroglobulinemia Therapeutics Revenue (2021-2032) & (US$ Million) Table 174. Russia Waldenstrom Macroglobulinemia Therapeutics Revenue (2021-2032) & (US$ Million) Table 175. Spain Waldenstrom Macroglobulinemia Therapeutics Revenue (2021-2032) & (US$ Million) Table 176. Netherlands Waldenstrom Macroglobulinemia Therapeutics Revenue (2021-2032) & (US$ Million) Table 177. Switzerland Waldenstrom Macroglobulinemia Therapeutics Revenue (2021-2032) & (US$ Million) Table 178. Sweden Waldenstrom Macroglobulinemia Therapeutics Revenue (2021-2032) & (US$ Million) Table 179. Poland Waldenstrom Macroglobulinemia Therapeutics Revenue (2021-2032) & (US$ Million) Table 180. China Waldenstrom Macroglobulinemia Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 181. China Waldenstrom Macroglobulinemia Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 182. China Waldenstrom Macroglobulinemia Therapeutics Sales by Type (2021-2026) & (W Units) Table 183. China Waldenstrom Macroglobulinemia Therapeutics Sales by Type (2027-2032) & (W Units) Table 184. China Waldenstrom Macroglobulinemia Therapeutics Sales Price by Type (2021-2026) & (US$/Unit) Table 185. China Waldenstrom Macroglobulinemia Therapeutics Sales Price by Type (2027-2032) & (US$/Unit) Table 186. China Waldenstrom Macroglobulinemia Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 187. China Waldenstrom Macroglobulinemia Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 188. China Waldenstrom Macroglobulinemia Therapeutics Sales by Application (2021-2026) & (W Units) Table 189. China Waldenstrom Macroglobulinemia Therapeutics Sales by Application (2027-2032) & (W Units) Table 190. China Waldenstrom Macroglobulinemia Therapeutics Sales Price by Application (2021-2026) & (US$/Unit) Table 191. China Waldenstrom Macroglobulinemia Therapeutics Sales Price by Application (2027-2032) & (US$/Unit) Table 192. Asia Waldenstrom Macroglobulinemia Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 193. Asia Waldenstrom Macroglobulinemia Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 194. Asia Waldenstrom Macroglobulinemia Therapeutics Sales by Type (2021-2026) & (W Units) Table 195. Asia Waldenstrom Macroglobulinemia Therapeutics Sales by Type (2027-2032) & (W Units) Table 196. Asia Waldenstrom Macroglobulinemia Therapeutics Sales Price by Type (2021-2026) & (US$/Unit) Table 197. Asia Waldenstrom Macroglobulinemia Therapeutics Sales Price by Type (2027-2032) & (US$/Unit) Table 198. Asia Waldenstrom Macroglobulinemia Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 199. Asia Waldenstrom Macroglobulinemia Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 200. Asia Waldenstrom Macroglobulinemia Therapeutics Sales by Application (2021-2026) & (W Units) Table 201. Asia Waldenstrom Macroglobulinemia Therapeutics Sales by Application (2027-2032) & (W Units) Table 202. Asia Waldenstrom Macroglobulinemia Therapeutics Sales Price by Application (2021-2026) & (US$/Unit) Table 203. Asia Waldenstrom Macroglobulinemia Therapeutics Sales Price by Application (2027-2032) & (US$/Unit) Table 204. Asia Waldenstrom Macroglobulinemia Therapeutics Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 205. Asia Waldenstrom Macroglobulinemia Therapeutics Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 206. Asia Waldenstrom Macroglobulinemia Therapeutics Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 207. Asia Waldenstrom Macroglobulinemia Therapeutics Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 208. Asia Waldenstrom Macroglobulinemia Therapeutics Sales by Country (2021-2026) & (W Units) Table 209. Asia Waldenstrom Macroglobulinemia Therapeutics Sales by Country (2027-2032) & (W Units) Table 210. Asia Waldenstrom Macroglobulinemia Therapeutics Sales Price by Country (2021-2026) & (US$/Unit) Table 211. Asia Waldenstrom Macroglobulinemia Therapeutics Sales Price by Country (2027-2032) & (US$/Unit) Table 212. Japan Waldenstrom Macroglobulinemia Therapeutics Revenue (2021-2032) & (US$ Million) Table 213. South Korea Waldenstrom Macroglobulinemia Therapeutics Revenue (2021-2032) & (US$ Million) Table 214. India Waldenstrom Macroglobulinemia Therapeutics Revenue (2021-2032) & (US$ Million) Table 215. Australia Waldenstrom Macroglobulinemia Therapeutics Revenue (2021-2032) & (US$ Million) Table 216. Taiwan Waldenstrom Macroglobulinemia Therapeutics Revenue (2021-2032) & (US$ Million) Table 217. Southeast Asia Waldenstrom Macroglobulinemia Therapeutics Revenue (2021-2032) & (US$ Million) Table 218. SAMEA Waldenstrom Macroglobulinemia Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 219. SAMEA Waldenstrom Macroglobulinemia Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 220. SAMEA Waldenstrom Macroglobulinemia Therapeutics Sales by Type (2021-2026) & (W Units) Table 221. SAMEA Waldenstrom Macroglobulinemia Therapeutics Sales by Type (2027-2032) & (W Units) Table 222. SAMEA Waldenstrom Macroglobulinemia Therapeutics Sales Price by Type (2021-2026) & (US$/Unit) Table 223. SAMEA Waldenstrom Macroglobulinemia Therapeutics Sales Price by Type (2027-2032) & (US$/Unit) Table 224. SAMEA Waldenstrom Macroglobulinemia Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 225. SAMEA Waldenstrom Macroglobulinemia Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 226. SAMEA Waldenstrom Macroglobulinemia Therapeutics Sales by Application (2021-2026) & (W Units) Table 227. SAMEA Waldenstrom Macroglobulinemia Therapeutics Sales by Application (2027-2032) & (W Units) Table 228. SAMEA Waldenstrom Macroglobulinemia Therapeutics Sales Price by Application (2021-2026) & (US$/Unit) Table 229. SAMEA Waldenstrom Macroglobulinemia Therapeutics Sales Price by Application (2027-2032) & (US$/Unit) Table 230. SAMEA Waldenstrom Macroglobulinemia Therapeutics Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 231. SAMEA Waldenstrom Macroglobulinemia Therapeutics Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 232. SAMEA Waldenstrom Macroglobulinemia Therapeutics Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 233. SAMEA Waldenstrom Macroglobulinemia Therapeutics Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 234. SAMEA Waldenstrom Macroglobulinemia Therapeutics Sales by Country (2021-2026) & (W Units) Table 235. SAMEA Waldenstrom Macroglobulinemia Therapeutics Sales by Country (2027-2032) & (W Units) Table 236. SAMEA Waldenstrom Macroglobulinemia Therapeutics Sales Price by Country (2021-2026) & (US$/Unit) Table 237. SAMEA Waldenstrom Macroglobulinemia Therapeutics Sales Price by Country (2027-2032) & (US$/Unit) Table 238. Brazil Waldenstrom Macroglobulinemia Therapeutics Revenue (2021-2032) & (US$ Million) Table 239. Argentina Waldenstrom Macroglobulinemia Therapeutics Revenue (2021-2032) & (US$ Million) Table 240. Chile Waldenstrom Macroglobulinemia Therapeutics Revenue (2021-2032) & (US$ Million) Table 241. Colombia Waldenstrom Macroglobulinemia Therapeutics Revenue (2021-2032) & (US$ Million) Table 242. Peru Waldenstrom Macroglobulinemia Therapeutics Revenue (2021-2032) & (US$ Million) Table 243. Saudi Arabia Waldenstrom Macroglobulinemia Therapeutics Revenue (2021-2032) & (US$ Million) Table 244. Israel Waldenstrom Macroglobulinemia Therapeutics Revenue (2021-2032) & (US$ Million) Table 245. UAE Waldenstrom Macroglobulinemia Therapeutics Revenue (2021-2032) & (US$ Million) Table 246. Turkey Waldenstrom Macroglobulinemia Therapeutics Revenue (2021-2032) & (US$ Million) Table 247. Iran Waldenstrom Macroglobulinemia Therapeutics Revenue (2021-2032) & (US$ Million) Table 248. Egypt Waldenstrom Macroglobulinemia Therapeutics Revenue (2021-2032) & (US$ Million) Table 249. Key Raw Materials Table 250. Raw Materials Key Suppliers Table 251. Waldenstrom Macroglobulinemia Therapeutics Distributors List Table 252. Waldenstrom Macroglobulinemia Therapeutics Customers List Table 253. Research Programs/Design for This Report Table 254. Authors List of This Report Table 255. Secondary Sources Table 256. Primary Sources List of Figures Figure 1. Waldenstrom Macroglobulinemia Therapeutics Image Figure 2. Global Waldenstrom Macroglobulinemia Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Waldenstrom Macroglobulinemia Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 4. CB-839 Image Figure 5. DI-B4 Image Figure 6. FV-162 Image Figure 7. Entospletinib Image Figure 8. Copanlisib Hydrochloride Image Figure 9. Everolimus Image Figure 10. Others Image Figure 11. Global Waldenstrom Macroglobulinemia Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Waldenstrom Macroglobulinemia Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 13. Clinic Image Figure 14. Hospital Image Figure 15. Others Image Figure 16. Global Waldenstrom Macroglobulinemia Therapeutics Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global Waldenstrom Macroglobulinemia Therapeutics Revenue (2021-2032) & (US$ Million) Figure 18. Global Waldenstrom Macroglobulinemia Therapeutics Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Waldenstrom Macroglobulinemia Therapeutics Revenue Market Share by Region: 2025 Versus 2032 Figure 20. Global Waldenstrom Macroglobulinemia Therapeutics Revenue Market Share by Region (2021-2032) Figure 21. Global Waldenstrom Macroglobulinemia Therapeutics Sales (2021-2032) & (W Units) Figure 22. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 23. Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share by Region (2021-2032) Figure 24. US & Canada & Mexico Waldenstrom Macroglobulinemia Therapeutics Sales YoY (2021-2032) & (W Units) Figure 25. Europe Waldenstrom Macroglobulinemia Therapeutics Sales YoY (2021-2032) & (W Units) Figure 26. China Waldenstrom Macroglobulinemia Therapeutics Sales YoY (2021-2032) & (W Units) Figure 27. Asia (Excluding China) Waldenstrom Macroglobulinemia Therapeutics Sales YoY (2021-2032) & (W Units) Figure 28. South America, Middle East and Africa Waldenstrom Macroglobulinemia Therapeutics Sales YoY (2021-2032) & (W Units) Figure 29. Global Waldenstrom Macroglobulinemia Therapeutics Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 30. Global Waldenstrom Macroglobulinemia Therapeutics Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 31. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 32. Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 33. Global Waldenstrom Macroglobulinemia Therapeutics Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Waldenstrom Macroglobulinemia Therapeutics Revenue Market Share by Type (2021-2032) Figure 35. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 36. Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 37. Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share by Type (2021-2032) Figure 38. Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 39. Global Waldenstrom Macroglobulinemia Therapeutics Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Waldenstrom Macroglobulinemia Therapeutics Revenue Market Share by Application (2021-2032) Figure 41. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 42. Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 43. Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share by Application (2021-2032) Figure 44. North America Waldenstrom Macroglobulinemia Therapeutics Revenue Share by Type (2021-2032) Figure 45. North America Waldenstrom Macroglobulinemia Therapeutics Sales Share by Type (2021-2032) Figure 46. North America Waldenstrom Macroglobulinemia Therapeutics Revenue Share by Application (2021-2032) Figure 47. North America Waldenstrom Macroglobulinemia Therapeutics Sales Share by Application (2021-2032) Figure 48. North America Waldenstrom Macroglobulinemia Therapeutics Revenue Share by Country (2021-2032) Figure 49. North America Waldenstrom Macroglobulinemia Therapeutics Sales Share by Country (2021-2032) Figure 50. Europe Waldenstrom Macroglobulinemia Therapeutics Revenue Share by Type (2021-2032) Figure 51. Europe Waldenstrom Macroglobulinemia Therapeutics Sales Share by Type (2021-2032) Figure 52. Europe Waldenstrom Macroglobulinemia Therapeutics Revenue Share by Application (2021-2032) Figure 53. Europe Waldenstrom Macroglobulinemia Therapeutics Sales Share by Application (2021-2032) Figure 54. Europe Waldenstrom Macroglobulinemia Therapeutics Revenue Share by Country (2021-2032) Figure 55. Europe Waldenstrom Macroglobulinemia Therapeutics Sales Share by Country (2021-2032) Figure 56. China Waldenstrom Macroglobulinemia Therapeutics Revenue Share by Type (2021-2032) Figure 57. China Waldenstrom Macroglobulinemia Therapeutics Sales Share by Type (2021-2032) Figure 58. China Waldenstrom Macroglobulinemia Therapeutics Revenue Share by Application (2021-2032) Figure 59. China Waldenstrom Macroglobulinemia Therapeutics Sales Share by Application (2021-2032) Figure 60. Asia Waldenstrom Macroglobulinemia Therapeutics Revenue Share by Type (2021-2032) Figure 61. Asia Waldenstrom Macroglobulinemia Therapeutics Sales Share by Type (2021-2032) Figure 62. Asia Waldenstrom Macroglobulinemia Therapeutics Revenue Share by Application (2021-2032) Figure 63. Asia Waldenstrom Macroglobulinemia Therapeutics Sales Share by Application (2021-2032) Figure 64. Asia Waldenstrom Macroglobulinemia Therapeutics Revenue Share by Country (2021-2032) Figure 65. Asia Waldenstrom Macroglobulinemia Therapeutics Sales Share by Country (2021-2032) Figure 66. SAMEA Waldenstrom Macroglobulinemia Therapeutics Revenue Share by Type (2021-2032) Figure 67. SAMEA Waldenstrom Macroglobulinemia Therapeutics Sales Share by Type (2021-2032) Figure 68. SAMEA Waldenstrom Macroglobulinemia Therapeutics Revenue Share by Application (2021-2032) Figure 69. SAMEA Waldenstrom Macroglobulinemia Therapeutics Sales Share by Application (2021-2032) Figure 70. SAMEA Waldenstrom Macroglobulinemia Therapeutics Revenue Share by Country (2021-2032) Figure 71. SAMEA Waldenstrom Macroglobulinemia Therapeutics Sales Share by Country (2021-2032) Figure 72. Waldenstrom Macroglobulinemia Therapeutics Value Chain Figure 73. Ma

Scope & coverage.

Types
  • CB-839
  • DI-B4
  • FV-162
  • Entospletinib
  • Copanlisib Hydrochloride
  • Everolimus
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Merck KGaA
  • Millennium Pharmaceuticals, Inc.
  • Karyopharm Therapeutics, Inc.
  • Incyte Corporation
  • IGF Oncology, LLC.
  • Idera Pharmaceuticals, Inc.
  • Hutchison MediPharma Limited
  • Gilead Sciences, Inc.
  • Genmab A/S
  • Genentech, Inc.
  • Celgene Corporation
  • Calithera Biosciences, Inc.
  • BeiGene(Beijing) Co.,Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Waldenstrom Macroglobulinemia Therapeutics Market by Type
  3. 1.2.1 Global Waldenstrom Macroglobulinemia Therapeutics Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 CB-839
  5. 1.2.3 DI-B4
  6. 1.2.4 FV-162
  7. 1.2.5 Entospletinib
  8. 1.2.6 Copanlisib Hydrochloride
  9. 1.2.7 Everolimus
  10. 1.2.8 Others
  11. 1.3 Waldenstrom Macroglobulinemia Therapeutics Market by Application
  12. 1.3.1 Global Waldenstrom Macroglobulinemia Therapeutics Market Size by Application, 2021 VS 2025 VS 2032
  13. 1.3.2 Clinic
  14. 1.3.3 Hospital
  15. 1.3.4 Others
  16. 1.4 Assumptions and Limitations
  17. 1.5 Study Goals and Objectives
2 Waldenstrom Macroglobulinemia Therapeutics Market Dynamics
  1. 2.1 Waldenstrom Macroglobulinemia Therapeutics Industry Trends
  2. 2.2 Waldenstrom Macroglobulinemia Therapeutics Industry Drivers
  3. 2.3 Waldenstrom Macroglobulinemia Therapeutics Industry Opportunities and Challenges
  4. 2.4 Waldenstrom Macroglobulinemia Therapeutics Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Waldenstrom Macroglobulinemia Therapeutics Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Region
  3. 3.2.1 Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Region (2021-2026)
  5. 3.2.3 Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Region (2027-2032)
  6. 3.2.4 Global Waldenstrom Macroglobulinemia Therapeutics Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Waldenstrom Macroglobulinemia Therapeutics Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Waldenstrom Macroglobulinemia Therapeutics Sales by Region
  9. 3.4.1 Global Waldenstrom Macroglobulinemia Therapeutics Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Waldenstrom Macroglobulinemia Therapeutics Sales by Region (2021-2026)
  11. 3.4.3 Global Waldenstrom Macroglobulinemia Therapeutics Sales by Region (2027-2032)
  12. 3.4.4 Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Manufacturers
  2. 4.1.1 Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Waldenstrom Macroglobulinemia Therapeutics Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Waldenstrom Macroglobulinemia Therapeutics Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Waldenstrom Macroglobulinemia Therapeutics Sales by Manufacturers
  6. 4.2.1 Global Waldenstrom Macroglobulinemia Therapeutics Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Waldenstrom Macroglobulinemia Therapeutics Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Waldenstrom Macroglobulinemia Therapeutics Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Waldenstrom Macroglobulinemia Therapeutics Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Waldenstrom Macroglobulinemia Therapeutics Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Waldenstrom Macroglobulinemia Therapeutics Manufacturers, Product Type & Application
  13. 4.7 Global Waldenstrom Macroglobulinemia Therapeutics Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Waldenstrom Macroglobulinemia Therapeutics Market CR5 and HHI
  16. 4.8.2 2025 Waldenstrom Macroglobulinemia Therapeutics Tier 1, Tier 2, and Tier 3
5 Waldenstrom Macroglobulinemia Therapeutics Market by Type
  1. 5.1 Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Type
  2. 5.1.1 Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Waldenstrom Macroglobulinemia Therapeutics Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Waldenstrom Macroglobulinemia Therapeutics Sales by Type
  6. 5.2.1 Global Waldenstrom Macroglobulinemia Therapeutics Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Waldenstrom Macroglobulinemia Therapeutics Sales by Type (2021-2032) & (W Units)
  8. 5.2.3 Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share by Type (2021-2032)
  9. 5.3 Global Waldenstrom Macroglobulinemia Therapeutics Price by Type
6 Waldenstrom Macroglobulinemia Therapeutics Market by Application
  1. 6.1 Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Application
  2. 6.1.1 Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Waldenstrom Macroglobulinemia Therapeutics Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Waldenstrom Macroglobulinemia Therapeutics Sales by Application
  6. 6.2.1 Global Waldenstrom Macroglobulinemia Therapeutics Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Waldenstrom Macroglobulinemia Therapeutics Sales by Application (2021-2032) & (W Units)
  8. 6.2.3 Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share by Application (2021-2032)
  9. 6.3 Global Waldenstrom Macroglobulinemia Therapeutics Price by Application
7 Company Profiles
  1. 7.1 Merck KGaA
  2. 7.1.1 Merck KGaA Company Information
  3. 7.1.2 Merck KGaA Business Overview
  4. 7.1.3 Merck KGaA Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Merck KGaA Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  6. 7.1.5 Merck KGaA Recent Developments
  7. 7.2 Millennium Pharmaceuticals, Inc.
  8. 7.2.1 Millennium Pharmaceuticals, Inc. Company Information
  9. 7.2.2 Millennium Pharmaceuticals, Inc. Business Overview
  10. 7.2.3 Millennium Pharmaceuticals, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Millennium Pharmaceuticals, Inc. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  12. 7.2.5 Millennium Pharmaceuticals, Inc. Recent Developments
  13. 7.3 Karyopharm Therapeutics, Inc.
  14. 7.3.1 Karyopharm Therapeutics, Inc. Company Information
  15. 7.3.2 Karyopharm Therapeutics, Inc. Business Overview
  16. 7.3.3 Karyopharm Therapeutics, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Karyopharm Therapeutics, Inc. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  18. 7.3.5 Karyopharm Therapeutics, Inc. Recent Developments
  19. 7.4 Incyte Corporation
  20. 7.4.1 Incyte Corporation Company Information
  21. 7.4.2 Incyte Corporation Business Overview
  22. 7.4.3 Incyte Corporation Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Incyte Corporation Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  24. 7.4.5 Incyte Corporation Recent Developments
  25. 7.5 IGF Oncology, LLC.
  26. 7.5.1 IGF Oncology, LLC. Company Information
  27. 7.5.2 IGF Oncology, LLC. Business Overview
  28. 7.5.3 IGF Oncology, LLC. Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 IGF Oncology, LLC. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  30. 7.5.5 IGF Oncology, LLC. Recent Developments
  31. 7.6 Idera Pharmaceuticals, Inc.
  32. 7.6.1 Idera Pharmaceuticals, Inc. Company Information
  33. 7.6.2 Idera Pharmaceuticals, Inc. Business Overview
  34. 7.6.3 Idera Pharmaceuticals, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Idera Pharmaceuticals, Inc. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  36. 7.6.5 Idera Pharmaceuticals, Inc. Recent Developments
  37. 7.7 Hutchison MediPharma Limited
  38. 7.7.1 Hutchison MediPharma Limited Company Information
  39. 7.7.2 Hutchison MediPharma Limited Business Overview
  40. 7.7.3 Hutchison MediPharma Limited Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Hutchison MediPharma Limited Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  42. 7.7.5 Hutchison MediPharma Limited Recent Developments
  43. 7.8 Gilead Sciences, Inc.
  44. 7.8.1 Gilead Sciences, Inc. Company Information
  45. 7.8.2 Gilead Sciences, Inc. Business Overview
  46. 7.8.3 Gilead Sciences, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Gilead Sciences, Inc. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  48. 7.8.5 Gilead Sciences, Inc. Recent Developments
  49. 7.9 Genmab A/S
  50. 7.9.1 Genmab A/S Company Information
  51. 7.9.2 Genmab A/S Business Overview
  52. 7.9.3 Genmab A/S Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Genmab A/S Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  54. 7.9.5 Genmab A/S Recent Developments
  55. 7.10 Genentech, Inc.
  56. 7.10.1 Genentech, Inc. Company Information
  57. 7.10.2 Genentech, Inc. Business Overview
  58. 7.10.3 Genentech, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Genentech, Inc. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  60. 7.10.5 Genentech, Inc. Recent Developments
  61. 7.11 Celgene Corporation
  62. 7.11.1 Celgene Corporation Company Information
  63. 7.11.2 Celgene Corporation Business Overview
  64. 7.11.3 Celgene Corporation Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Celgene Corporation Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  66. 7.11.5 Celgene Corporation Recent Developments
  67. 7.12 Calithera Biosciences, Inc.
  68. 7.12.1 Calithera Biosciences, Inc. Company Information
  69. 7.12.2 Calithera Biosciences, Inc. Business Overview
  70. 7.12.3 Calithera Biosciences, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Calithera Biosciences, Inc. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  72. 7.12.5 Calithera Biosciences, Inc. Recent Developments
  73. 7.13 BeiGene(Beijing) Co.,Ltd
  74. 7.13.1 BeiGene(Beijing) Co.,Ltd Company Information
  75. 7.13.2 BeiGene(Beijing) Co.,Ltd Business Overview
  76. 7.13.3 BeiGene(Beijing) Co.,Ltd Waldenstrom Macroglobulinemia Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 BeiGene(Beijing) Co.,Ltd Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  78. 7.13.5 BeiGene(Beijing) Co.,Ltd Recent Developments
8 North America
  1. 8.1 North America Waldenstrom Macroglobulinemia Therapeutics Market Size by Type
  2. 8.1.1 North America Waldenstrom Macroglobulinemia Therapeutics Revenue by Type (2021-2032)
  3. 8.1.2 North America Waldenstrom Macroglobulinemia Therapeutics Sales by Type (2021-2032)
  4. 8.1.3 North America Waldenstrom Macroglobulinemia Therapeutics Price by Type (2021-2032)
  5. 8.2 North America Waldenstrom Macroglobulinemia Therapeutics Market Size by Application
  6. 8.2.1 North America Waldenstrom Macroglobulinemia Therapeutics Revenue by Application (2021-2032)
  7. 8.2.2 North America Waldenstrom Macroglobulinemia Therapeutics Sales by Application (2021-2032)
  8. 8.2.3 North America Waldenstrom Macroglobulinemia Therapeutics Price by Application (2021-2032)
  9. 8.3 North America Waldenstrom Macroglobulinemia Therapeutics Market Size by Country
  10. 8.3.1 North America Waldenstrom Macroglobulinemia Therapeutics Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Waldenstrom Macroglobulinemia Therapeutics Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Waldenstrom Macroglobulinemia Therapeutics Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Waldenstrom Macroglobulinemia Therapeutics Market Size by Type
  2. 9.1.1 Europe Waldenstrom Macroglobulinemia Therapeutics Revenue by Type (2021-2032)
  3. 9.1.2 Europe Waldenstrom Macroglobulinemia Therapeutics Sales by Type (2021-2032)
  4. 9.1.3 Europe Waldenstrom Macroglobulinemia Therapeutics Price by Type (2021-2032)
  5. 9.2 Europe Waldenstrom Macroglobulinemia Therapeutics Market Size by Application
  6. 9.2.1 Europe Waldenstrom Macroglobulinemia Therapeutics Revenue by Application (2021-2032)
  7. 9.2.2 Europe Waldenstrom Macroglobulinemia Therapeutics Sales by Application (2021-2032)
  8. 9.2.3 Europe Waldenstrom Macroglobulinemia Therapeutics Price by Application (2021-2032)
  9. 9.3 Europe Waldenstrom Macroglobulinemia Therapeutics Market Size by Country
  10. 9.3.1 Europe Waldenstrom Macroglobulinemia Therapeutics Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Waldenstrom Macroglobulinemia Therapeutics Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Waldenstrom Macroglobulinemia Therapeutics Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Waldenstrom Macroglobulinemia Therapeutics Market Size by Type
  2. 10.1.1 China Waldenstrom Macroglobulinemia Therapeutics Revenue by Type (2021-2032)
  3. 10.1.2 China Waldenstrom Macroglobulinemia Therapeutics Sales by Type (2021-2032)
  4. 10.1.3 China Waldenstrom Macroglobulinemia Therapeutics Price by Type (2021-2032)
  5. 10.2 China Waldenstrom Macroglobulinemia Therapeutics Market Size by Application
  6. 10.2.1 China Waldenstrom Macroglobulinemia Therapeutics Revenue by Application (2021-2032)
  7. 10.2.2 China Waldenstrom Macroglobulinemia Therapeutics Sales by Application (2021-2032)
  8. 10.2.3 China Waldenstrom Macroglobulinemia Therapeutics Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Waldenstrom Macroglobulinemia Therapeutics Market Size by Type
  2. 11.1.1 Asia Waldenstrom Macroglobulinemia Therapeutics Revenue by Type (2021-2032)
  3. 11.1.2 Asia Waldenstrom Macroglobulinemia Therapeutics Sales by Type (2021-2032)
  4. 11.1.3 Asia Waldenstrom Macroglobulinemia Therapeutics Price by Type (2021-2032)
  5. 11.2 Asia Waldenstrom Macroglobulinemia Therapeutics Market Size by Application
  6. 11.2.1 Asia Waldenstrom Macroglobulinemia Therapeutics Revenue by Application (2021-2032)
  7. 11.2.2 Asia Waldenstrom Macroglobulinemia Therapeutics Sales by Application (2021-2032)
  8. 11.2.3 Asia Waldenstrom Macroglobulinemia Therapeutics Price by Application (2021-2032)
  9. 11.3 Asia Waldenstrom Macroglobulinemia Therapeutics Market Size by Country
  10. 11.3.1 Asia Waldenstrom Macroglobulinemia Therapeutics Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Waldenstrom Macroglobulinemia Therapeutics Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Waldenstrom Macroglobulinemia Therapeutics Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Waldenstrom Macroglobulinemia Therapeutics Market Size by Type
  2. 12.1.1 SAMEA Waldenstrom Macroglobulinemia Therapeutics Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Waldenstrom Macroglobulinemia Therapeutics Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Waldenstrom Macroglobulinemia Therapeutics Price by Type (2021-2032)
  5. 12.2 SAMEA Waldenstrom Macroglobulinemia Therapeutics Market Size by Application
  6. 12.2.1 SAMEA Waldenstrom Macroglobulinemia Therapeutics Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Waldenstrom Macroglobulinemia Therapeutics Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Waldenstrom Macroglobulinemia Therapeutics Price by Application (2021-2032)
  9. 12.3 SAMEA Waldenstrom Macroglobulinemia Therapeutics Market Size by Country
  10. 12.3.1 SAMEA Waldenstrom Macroglobulinemia Therapeutics Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Waldenstrom Macroglobulinemia Therapeutics Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Waldenstrom Macroglobulinemia Therapeutics Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Waldenstrom Macroglobulinemia Therapeutics Value Chain Analysis
  2. 13.1.1 Waldenstrom Macroglobulinemia Therapeutics Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Waldenstrom Macroglobulinemia Therapeutics Production Mode & Process
  6. 13.2 Waldenstrom Macroglobulinemia Therapeutics Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Waldenstrom Macroglobulinemia Therapeutics Distributors
  9. 13.2.3 Waldenstrom Macroglobulinemia Therapeutics Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst